Confluence Wealth Services Inc. Has $6.37 Million Stock Position in Merck & Co., Inc. $MRK

Confluence Wealth Services Inc. lifted its stake in shares of Merck & Co., Inc. (NYSE:MRK) by 12.0% during the second quarter, Holdings Channel.com reports. The firm owned 49,534 shares of the company’s stock after acquiring an additional 5,322 shares during the period. Confluence Wealth Services Inc.’s holdings in Merck & Co., Inc. were worth $6,365,000 as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the company. Kingdom Financial Group LLC. bought a new stake in shares of Merck & Co., Inc. during the fourth quarter valued at approximately $25,000. Prosperity Bancshares Inc acquired a new position in shares of Merck & Co., Inc. during the fourth quarter worth approximately $26,000. Abound Financial LLC bought a new position in shares of Merck & Co., Inc. in the 4th quarter worth $26,000. IFC & Insurance Marketing Inc. bought a new position in shares of Merck & Co., Inc. in the 4th quarter worth $31,000. Finally, High Note Wealth LLC grew its position in Merck & Co., Inc. by 58.9% in the 4th quarter. High Note Wealth LLC now owns 294 shares of the company’s stock valued at $31,000 after purchasing an additional 109 shares during the period. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Key Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Analyst upgrade and higher valuations: Daiwa Securities upgraded MRK from “neutral” to “outperform” and set a $143 price target. Other analysts have raised fair-value estimates into the $140–$155 range, citing pipeline progress, business-development activity and late-stage therapies. Daiwa Securities upgrade
• Positive Sentiment: Business momentum remains supportive: MRK recently touched a record high, while Keytruda demand, oncology products, new launches and Animal Health helped drive quarterly revenue of $16.61 billion, above the $16.37 billion consensus estimate. The company also exceeded earnings expectations and reported 5.1% year-over-year revenue growth. Merck fair value and pipeline progress
• Positive Sentiment: Income and diversification appeal: Merck declared its regular $0.85 quarterly dividend, or $3.40 annualized, while potential expansion of ENFLONSIA for RSV prevention could broaden growth beyond oncology.
• Neutral Sentiment: Insider selling warrants monitoring: EVP Chirfi Guindo sold 10,000 shares for $1.35 million, following substantial sales by executives Jennifer Zachary and Richard Deluca. Each executive retained a meaningful stake, so the transactions may reflect personal financial decisions rather than a deteriorating outlook. Merck insider selling report
• Negative Sentiment: Keytruda concentration is a future risk: Patent expiration and increasing competition could pressure Merck’s largest growth driver. Investors will need evidence that the pipeline and newer products can offset eventual Keytruda sales declines. Keytruda growth outlook

Wall Street Analysts Forecast Growth

A number of analysts have commented on the stock. Argus boosted their price target on shares of Merck & Co., Inc. from $130.00 to $145.00 and gave the company a “buy” rating in a research note on Tuesday, August 11th. Daiwa Securities Group raised shares of Merck & Co., Inc. from a “neutral” rating to an “outperform” rating and set a $143.00 price objective on the stock in a research note on Wednesday. Cantor Fitzgerald reiterated a “neutral” rating and set a $120.00 price objective on shares of Merck & Co., Inc. in a report on Monday, July 6th. Wall Street Zen cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a report on Monday, July 20th. Finally, Guggenheim boosted their target price on shares of Merck & Co., Inc. from $145.00 to $146.00 and gave the stock a “buy” rating in a research report on Wednesday, August 5th. Fifteen investment analysts have rated the stock with a Buy rating and seven have given a Hold rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $135.50.

Insiders Place Their Bets

In other Merck & Co., Inc. news, EVP David Michael Williams sold 52,847 shares of the stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.77, for a total value of $6,805,108.19. Following the completion of the sale, the executive vice president owned 31,716 shares in the company, valued at approximately $4,084,069.32. This trade represents a 62.49% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, EVP David R. Maraldo sold 18,706 shares of the stock in a transaction dated Wednesday, August 5th. The shares were sold at an average price of $128.72, for a total transaction of $2,407,836.32. Following the completion of the sale, the executive vice president owned 18,212 shares of the company’s stock, valued at approximately $2,344,248.64. This trade represents a 50.67% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 228,238 shares of company stock worth $29,977,783 in the last ninety days. 0.17% of the stock is owned by corporate insiders.

Merck & Co., Inc. Price Performance

Shares of NYSE:MRK opened at $135.78 on Friday. The company has a current ratio of 1.32, a quick ratio of 1.06 and a debt-to-equity ratio of 1.22. The stock has a market cap of $334.98 billion, a PE ratio of 108.62, a price-to-earnings-growth ratio of 5.86 and a beta of 0.19. The stock’s fifty day simple moving average is $125.54 and its two-hundred day simple moving average is $119.94. Merck & Co., Inc. has a 1-year low of $77.58 and a 1-year high of $135.97.

Merck & Co., Inc. (NYSE:MRK) last posted its earnings results on Tuesday, August 4th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.26) by $0.13. The firm had revenue of $16.61 billion during the quarter, compared to analyst estimates of $16.37 billion. Merck & Co., Inc. had a net margin of 4.77% and a return on equity of 16.73%. The business’s revenue was up 5.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $2.13 EPS. Merck & Co., Inc. has set its FY 2026 guidance at 2.660-2.760 EPS. As a group, analysts forecast that Merck & Co., Inc. will post 2.77 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Wednesday, October 7th. Investors of record on Tuesday, September 15th will be issued a dividend of $0.85 per share. The ex-dividend date is Tuesday, September 15th. This represents a $3.40 annualized dividend and a yield of 2.5%. Merck & Co., Inc.’s payout ratio is 272.00%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.